絞り込み

16640

広告

Stereospecific synthesis and bio-activity of novel beta(3)-adrenoceptor agonists and inverse agonists.

著者 Perrone MG , Santandrea E , Bleve L , Vitale P , Colabufo NA , Jockers R , Milazzo FM , Sciarroni AF , Scilimati A
Bioorg Med Chem.2008 Mar 1 ; 16(5):2473-88.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Dipartimento Farmaco-Chimico, Università di Bari, Via E.Orabona 4, 70125 Bari, Italy.

スターを付ける スターを付ける     (9view , 0users)

Chemical Information

Full Text Sources

Miscellaneous

Other Literature Sources

Since it is widely distributed into the body, beta(3)-adrenoceptor is becoming an attractive target for the treatment of several pathologies such as obesity, type 2 diabetes, metabolic syndrome, cachexia, overactive bladder, ulcero-inflammatory disorder of the gut, preterm labour, anxiety and depressive disorders, and heart failure. New compounds belonging to the class of arylethanolamines bearing one or two stereogenic centres were prepared in good yields as racemates and optically active forms. They were, then, evaluated for their intrinsic activity towards beta(3)-adrenoceptor and their affinity for beta(1)- and beta(2)-adrenergic receptors. Stereochemical features were found to play a crucial role in determining the behaviour of such compounds. In particular, alpha-racemic, (alphaR)- and (alphaS)-2-{4-[2-(2-hydroxy-2-phenylethylamino)ethyl]phenoxy}-2- methylpropanoic acid, (alpha-rac, beta-rac)-, (alphaR, betaS)- and (alphaR, betaR)- 2-{4-[2-(2-hydroxy-2-phenylethylamino)ethyl]phenoxy}propanoic acid were found to be endowed with beta(3)-adrenoceptor agonistic activity. Whereas, (alphaS, betaS)- and (alphaS, betaR)-2-{4-[2-(2-hydroxy-2-phenylethylamino)ethyl]phenoxy}propanoic acid behaved as beta(3)-adrenoceptor inverse agonists. Such compounds showed no affinity for beta(1)- and beta(2)-adrenergic receptor, respectively. Thus, resulting highly selective beta(3)-adrenoceptor ligands.
PMID: 18083578 [PubMed - indexed for MEDLINE]
印刷用ページを開く Endnote用テキストダウンロード